IMAC - International Market Access Consulting

Louise Perrault delivered a groundbreaking presentation at the World Orphan Drug Congress Europe 2024, titled SmPC at the Heart of EU JCA: Shaping Decisions, Driving Access. 💡 Her innovative talk was the first to explore the strategic link between the drafting of the Summary of Product Characteristics (SmPC) and the selection of PICO (Population, Intervention, Comparator, and Outcome) in the EU Joint Clinical Assessment (JCA). Louise emphasized that proactive and forward-thinking drafting of the SmPC is critical, not just for regulatory compliance but also for shaping how decisions are made by #EUJCA. By carefully aligning #SmPC content with the anticipated PICO framework, manufacturers can influence the outcomes of clinical assessments, ultimately driving market access and ensuring the right patients receive timely treatments. This visionary approach redefines how we think about market access strategies, underscoring the importance of being strategically minded from the earliest stages of product development. Louise’s talk was a game-changer, offering a fresh perspective on how to align regulatory and market access goals for maximum impact. 🌍 After the talk, many attendees expressed interest in learning more. IMAC is presenting a webinar on Tuesday, October 29th at 16:00 CET (GMT+2) to explore how optimizing the Summary of Product Characteristics (SmPC) can shape strategy for the European Joint Clinical Assessment (JCA). The session will be led by Louise Perrault, IMAC's founder and CEO, and Nicole Tunstall, Vice President, both with decades of experience in market access consulting. We look forward to sharing valuable insights that will help enhance your market access strategy. Free registration at: https://lnkd.in/dpVdHyWh #WODC #OrphanDrugs #EUJCA #MarketAccess #PatientCare

IMAC's CEO, Louise Perrault, will be presenting at the World Orphan Drug Congress Europe in the Access & Pricing section on "SmPC at the Heart of EU JCA: Shaping Decisions, Driving Access" tomorrow October 23rd at 17:10 in Theatre 6. She will dive into how the EU Joint Clinical Assessment (JCA) is shaping access to life-saving medicines across Europe. 🌍💊 Come say hi to Louise and the IMAC team - we would love to connect with you and discuss the future of patient care! Looking forward to an inspiring event filled with innovation and collaboration! #WorldOrphanDrugCongress #WODC #OrphanDrug #RareDisease

We are excited to invite you to our upcoming webinar, Strategic SmPC Optimization as the Core of EU JCA: Crafting a Blueprint for Market Access Success, hosted by International Market Access Consulting (IMAC). Join us on October 29th at 16:00 CET (GMT+2) to explore how optimizing the Summary of Product Characteristics (#SmPC) can shape strategy for the European Joint Clinical Assessment (#JCA). Starting in January 2025, the EU will implement a JCA for new oncology and Advanced Therapy Medicinal Products (#ATMPs). This webinar will cover how SmPC development can impact PICO criteria—patient, intervention, comparator, and outcome—and the role it plays in market access success. The session will be led by Louise Perrault, IMAC's founder and CEO, with decades of experience in market access consulting. Moderating will be Nicole Tunstall, IMAC’s Vice President, who will guide us through the key strategies for optimizing SmPCs ahead of the JCA process. We look forward to sharing valuable insights that will help enhance your market access strategy. Don’t miss out! Free registration available at https://tally.so/r/nrdea2

Exciting News! 🚀 We are thrilled to announce that Louise Perrault, Founder and CEO of IMAC - International Market Access Consulting, has been invited to speak at the upcoming World Orphan Drug Congress Europe in Barcelona, taking place from October 23-25, 2024. Louise’s insights into the world of orphan drugs and market access strategies have been transformative for our industry, and this is a fantastic opportunity for attendees to gain valuable perspectives from one of the leading voices in the field. Looking forward to an inspiring event filled with innovation and collaboration! 🌍 💊 #WorldOrphanDrugCongress #OrphanDrugs #MarketAccess #Pharma #Barcelona2024

🚀 We're excited to share the latest insights from our CEO, Louise Perrault, in this must-watch Masterclass on #reimbursement in #healthcare. Dive into the complexities of navigating market access and ensuring that innovative therapies reach those who need them most. Watch the full session here: https://lnkd.in/dYNqSuTp 📢 Don’t miss out on this valuable knowledge from one of the leading experts in the field! #MarketAccess #HealthcareMarket #NewTherapy #Leadership

🌟 Spotlight on Christelle Iliza: A Strategic Leader in Pharmaceutical Market Access 🌟 Today, we are pleased to highlight Christelle Iliza, who has been a valued member of the IMAC team for over 10 years. Her expertise as a Senior Consultant specializing in Market Access submissions is instrumental to navigating the complex healthcare system in Canada and beyond. Christelle's extensive background in the requirements and process for #HTA submissions positions her as a key player in the market launch of new therapies, optimizing the review process, thereby facilitating innovative treatments to successfully reach the market, benefiting patients worldwide. Her deep understanding of reimbursement processes and regulatory requirements enables her to navigate with precision, consistently delivering successful outcomes. What sets Christelle apart is her meticulous attention to detail and her ability to remain calm and focused under pressure. Her work in managing complex submission processes is marked by thoroughness and accuracy, ensuring that every detail is carefully considered and executed. Christelle’s expertise in the submission process is unmatched, and her commitment to precision ensures that all projects meet the highest standards of quality and compliance. In addition to her technical skills, Christelle is known for her methodical approach to problem-solving. She excels in environments where accuracy and attention to detail are paramount, consistently delivering results that exceed expectations. Her ability to work effectively under tight deadlines, without compromising on quality, makes her an invaluable asset to our team. Christelle’s forward-thinking approach and commitment to continuous learning ensure that she remains a leader in the ever-evolving field of pharmaceutical market access. Her contributions have played a crucial role in the success of our initiatives, and her impact is felt beyond the IMAC team. We are fortunate to have Christelle Iliza as a part of our team. Her dedication, expertise, and leadership are instrumental in advancing our mission to improve global #healthcare access. Join us in acknowledging Christelle’s significant achievements and her ongoing contributions to the field of #pharmaceutical market access.

🌟 New article: In the dynamic realm of pharmaceuticals, two critical processes often find themselves at odds: Sales Forecasting and Budget Impact Analysis (BIA). Let’s dive into why this tension exists and why balancing both is crucial!

💡 One of the hot topics at the recent Cell and Gene Therapy Pricing & Reimbursement Summit was the key role real-world evidence (#RWE) often plays in addressing uncertainty around the durability and true clinical value of these therapies. Advanced therapy medicinal products (#ATMPs) for rare diseases have driven increased complexity in health technology assessment (HTA). Generating and collecting RWE is becoming more important for making better decisions in healthcare.   Certainly, #HTA agencies in Europe and North America are increasingly turning towards RWE to assist in their decision-making process.   IMAC has been at the forefront of delivering RWE solutions for clients navigating market access challenges. We provide strategic advice to address evidence gaps, adding value at every stage of a therapy's life cycle. Our team of experts will design the study, collect and analyze the data, and effectively communicate the RWE, enhancing your position from launch through to sustained market success.   We invite you to access a compelling case study on the strategic planning and execution of a retrospective, chart review study in patients with a rare soft tissue sarcoma, designed to address a critical lack of comparative efficacy in a patient population with a heavy burden of disease and high unmet need. See the full case study: https://lnkd.in/d4Xu4kq3

IMAC - International Market Access Consulting Vice President, Nicole Tunstall reflects on the recent Cell & Gene Therapy Pricing & Reimbursement Summit. Many interesting conversations on the current status and future of Cell & Gene Therapy launches in the US and worldwide!

Next week, Nicole Tunstall will be at the Cell & Gene Therapy Pricing and Reimbursement Summit from June 25-27 in Washington, DC. Let’s connect and discuss how IMAC can help you navigate the evolving regulatory landscape and ensure the success of your commercial launches. See you there! #MarketAccess #CellandGenePricing #InflationReductionAct